Mutant-selective degradation by BRAF-targeting PROTACs

Over 300 BRAF missense mutations have been identified in patients, yet currently approved drugs target V600 mutants alone. Moreover, acquired resistance inevitably emerges, primarily due to RAF lesions that prevent inhibition of BRAF V600 with current treatments. Therefore, there is a need for new t...

Descripción completa

Detalles Bibliográficos
Autores principales: Alabi, Shanique, Jaime-Figueroa, Saul, Yao, Zhan, Gao, Yijun, Hines, John, Samarasinghe, Kusal T. G., Vogt, Lea, Rosen, Neal, Crews, Craig M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876048/
https://www.ncbi.nlm.nih.gov/pubmed/33568647
http://dx.doi.org/10.1038/s41467-021-21159-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876048/
https://www.ncbi.nlm.nih.gov/pubmed/33568647
http://dx.doi.org/10.1038/s41467-021-21159-7

Ejemplares similares